Maxine Gowen
CIK: 0001280044
Transaction Breakdown
High conviction signal
Position reduction
Derivative conversions
Compensation grants
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Discretionary Trading P&L
Holdings
Transaction History (15 total)
- Jun 5, 2026ACRS
Aclaris Therapeutics, Inc.
Exercise(M)Direct11.6K shares- - Jun 4, 2026ACRS
Aclaris Therapeutics, Inc.
Award(A)DirectStock Option (Right to Buy)
42.4K shares- - Jun 4, 2026ACRS
Aclaris Therapeutics, Inc.
Award(A)DirectRestricted Stock Units
11K shares- - May 19, 2026PASG
Passage BIO, Inc.
Award(A)DirectDirector Stock Option (right to buy)
10.5K shares- - Dec 12, 2025MRUS
Merus N.V.
Disposition(D)DirectShare Option (right to buy)
14.4K shares- - Dec 12, 2025MRUS
Merus N.V.
Disposition(D)DirectShare Option (right to buy)
13.2K shares- - Dec 12, 2025MRUS
Merus N.V.
Disposition(D)DirectShare Option (right to buy)
8.8K shares- - Dec 12, 2025MRUS
Merus N.V.
Disposition(D)DirectShare Option (right to buy)
16.6K shares- - Dec 12, 2025MRUS
Merus N.V.
Disposition(D)DirectShare Option (right to buy)
12.2K shares- - Dec 12, 2025MRUS
Merus N.V.
Disposition(D)DirectShare Option (right to buy)
8K shares- - Jun 6, 2025ACRS
Aclaris Therapeutics, Inc.
Exercise(M)Direct4.8K shares- - Jun 5, 2025ACRS
Aclaris Therapeutics, Inc.
Award(A)DirectStock Option (Right to Buy)
42.4K shares- - Jun 5, 2025ACRS
Aclaris Therapeutics, Inc.
Award(A)DirectRestricted Stock Units
11.6K shares- - May 28, 2025PASG
Passage BIO, Inc.
Award(A)DirectDirector Stock Option (right to buy)
201.9K shares- - May 22, 2025MRUS
Merus N.V.
Award(A)DirectShare Option (right to buy)
13.2K shares-
| Type | Shares | Price | Ownership | |||
|---|---|---|---|---|---|---|
| Jun 5, 2026 |  ACRS Aclaris Therapeutics, Inc. | Exercise(M) | 11,580 | - | $0 | Direct |
| Jun 4, 2026 | ACRS Aclaris Therapeutics, Inc. | Award(A) Stock Option (Right to Buy) | 42,350 | - | - | Direct |
| Jun 4, 2026 | ACRS Aclaris Therapeutics, Inc. | Award(A) Restricted Stock Units | 10,987 | - | - | Direct |
| May 19, 2026 |  PASG Passage BIO, Inc. | Award(A) Director Stock Option (right to buy) | 10,539 | - | - | Direct |
| Dec 12, 2025 |  MRUS Merus N.V. | Disposition(D) Share Option (right to buy) | 14,414 | - | - | Direct |
| Dec 12, 2025 | MRUS Merus N.V. | Disposition(D) Share Option (right to buy) | 13,193 | - | - | Direct |
| Dec 12, 2025 | MRUS Merus N.V. | Disposition(D) Share Option (right to buy) | 8,844 | - | - | Direct |
| Dec 12, 2025 | MRUS Merus N.V. | Disposition(D) Share Option (right to buy) | 16,604 | - | - | Direct |
| Dec 12, 2025 | MRUS Merus N.V. | Disposition(D) Share Option (right to buy) | 12,240 | - | - | Direct |
| Dec 12, 2025 | MRUS Merus N.V. | Disposition(D) Share Option (right to buy) | 7,957 | - | - | Direct |
| Jun 6, 2025 | ACRS Aclaris Therapeutics, Inc. | Exercise(M) | 4,793 | - | - | Direct |
| Jun 5, 2025 | ACRS Aclaris Therapeutics, Inc. | Award(A) Stock Option (Right to Buy) | 42,350 | - | - | Direct |
| Jun 5, 2025 | ACRS Aclaris Therapeutics, Inc. | Award(A) Restricted Stock Units | 11,580 | - | - | Direct |
| May 28, 2025 | PASG Passage BIO, Inc. | Award(A) Director Stock Option (right to buy) | 201,857 | - | - | Direct |
| May 22, 2025 | MRUS Merus N.V. | Award(A) Share Option (right to buy) | 13,193 | - | - | Direct |
1-15 of 15 transactions
About GOWEN MAXINE
GOWEN MAXINE (SEC CIK 0001280044) files insider reports with the SEC as Director of Aclaris Therapeutics, Inc. (ACRS), Director of Passage BIO, Inc. (PASG) and Director of Merus N.V. (MRUS).
Signal8 holds 6 ownership filings by GOWEN MAXINE, all Form 4s, filed between May 27, 2025 and Jun 8, 2026. Those filings report 15 transactions, from May 22, 2025 to Jun 5, 2026. Signal8's Form 4 history starts in Sep 2024.
The business address on GOWEN MAXINE's filings is in WAYNE, PA.
Recent filings by GOWEN MAXINE
- Jun 5, 2026: Option exercise of ACRS shares (Form 4, code M).
- Jun 4, 2026: Grants or awards of ACRS derivative securities (2 lines, Form 4, code A).
- May 19, 2026: Grant or award of PASG derivative securities (Form 4, code A).
- Dec 12, 2025: Disposition to issuer transactions of MRUS derivative securities (6 lines, Form 4, code D).
- Jun 6, 2025: Option exercise of ACRS shares (Form 4, code M).
Other insiders filing for Aclaris Therapeutics, Inc. (ACRS)
- Kolbeck Roland Wilhelm, Chief Scientific Officer
- SCHIFF ANDREW N, Director
- Mehra Anand, Director
- Molineaux Christopher P., Director
- Humphries William D., Director
- MILANO VINCENT, Director